Hemobiotech, Inc., a biopharmaceutical company, engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Service Center in Texas. It focuses primarily on the development of HemoTech, an oxygen-carrying solution that performs like red blood cells. The company was founded in 2001 and is headquartered in Dallas, Texas.